Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc ...
Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...
A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.
The COMPARE trial is an open-label, randomized, controlled Phase 1/2 study evaluating KYV-101 against the anti-CD20 monoclonal antibody rituximab in patients with anti-citrullinated protein antibody ...
The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...
All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the ...
ORR was higher in patients in the 177 Lu-edotreotide arm vs. everolimus across subgroups, including those with pancreatic NETs, Grade 1 tumors, Grade 2 tumors, and those who had received prior therapy ...
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...
At ACR 2025, early data of CTA313, a universal CD19/BCMA CAR-T therapy, demonstrate safety and strong responses in refractory ...
Marla Sofer, whose leadership experience includes roles at BlackRock and JPMorgan, explains how gamification and AI can help ...
The traditional Mayan ceremony was held to mark the conviction of three men for committing crimes against the women in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback